LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

26.61 -22.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.27

Max

34.23

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	11.36 110.024
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+65.47% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	387M 2.1B
Eelmine avamishind	48.87
Eelmine sulgemishind	26.61

Uudiste sentiment

By Acuity

50%

141 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. veebr 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. veebr 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. veebr 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. veebr 2026, 23:21 UTC

Tulu

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. veebr 2026, 23:20 UTC

Tulu

Nickel Industries 2025 Operating Profit US$126.4 Million

22. veebr 2026, 23:19 UTC

Tulu

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. veebr 2026, 23:19 UTC

Tulu

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. veebr 2026, 23:18 UTC

Tulu

Nickel Industries Won't Pay a Final Dividend

22. veebr 2026, 23:16 UTC

Tulu

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. veebr 2026, 21:35 UTC

Tulu

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. veebr 2026, 21:34 UTC

Tulu

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. veebr 2026, 21:34 UTC

Tulu

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. veebr 2026, 21:33 UTC

Tulu

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. veebr 2026, 21:33 UTC

Tulu

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. veebr 2026, 21:28 UTC

Tulu

Ampol Final Dividend A$0.60/Share

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Revenue A$31.37 Billion, Down 10%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. veebr 2026, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

65.47% tõus

12 kuu keskmine prognoos

Keskmine 48.25 USD 65.47%

Kõrge 55 USD

Madal 42 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

141 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.